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Abstract The antiprogestatin drug RU 486 was examined for its effect on doxorubicin cellular etention and cytotoxicity inmultidrug resistant cells 
overexpressing P-glycoprotein (P-gp). RU 486 was shown to strongly enhance intracellular ccumulation f doxorubicin i both rat hepatoma RHC1 
and human leukemia K562 R7 drug-resistant cells but had no action in SDVI drug-sensitive liver ceils. The antiprogestatin drug when used at 
10 gM, a concentration close to plasma concentrations achievable inhumans, was able to hugely increase the sensitivity of RHC1 cells to doxorubicin. 
RU 486 appeared to prevent the P-gp-mediated doxorubicin efflux out of RHC1 cells and was demonstrated to interfere directly with P-gp drug 
binding sites since it blocked P-gp labelling by the photoactivable P-gp ligand azidopine. These results thus demonstrate hat RU 486 can 
downmodulate anticancer drug resistance through inhibition of P-gp function. 
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1. Introduction 2. Materials and methods 
Resistance to chemotherapy is a major cause of failure in the 
treatment of many human cancers. A major mechanism in- 
volved in this drug resistance is linked to the overexpression f
a plasma membrane glycoprotein termed P-glycoprotein (P-gp) 
[1-3]. P-gp, encoded by mdr genes, is thought to act as an 
energy-dependent drug efflux pump with broad specificity; it 
transports various structurally and functionally unrelated anti- 
tumor compounds such as doxorubicin and l~nca alkaloids out 
of the cell, thus conferring a multidrug resistance phenotype 
(MDR). 
A wide range of drugs termed chemosensitizers or modulator 
agents including verapamil, cyclosporin and quinidine, have 
been used to block P-gp function and thus to restore sensitivity 
to cytotoxic drugs [4]. Some of these reversing compounds have 
been demonstrated to inhibit the labelling of P-gp by MDR- 
related drugs, thereby suggesting that they act through compe- 
tition for drug binding sites on P-gp [5]. Some endogenous 
compounds uch as steroid hormones also interact with P-gp 
[6]. Corticosteroids and mineralocorticoids are substrates for 
P-gp transport [7] while progesterone can directly label human 
P-gp [8]. Some steroid antagonists also interfere with P-gp func- 
tion. Indeed, P-gp-mediated drug resistance has been demon- 
strated to be overcome by antiestrogen compounds uch as 
tamoxifen and toremifen [9], which display structural features 
usually described in modulator agents, particularly hydropho- 
bicity and presence of phenyl rings [10]. Since these character- 
istics are also shared by RU 486, an antihormone compound 
with antiprogestatin property [11], we have questioned as to 
whether RU 486 could modulate anticancer drug accumulation 
and activity in P-gp overexpressing cells. 
2.1. Chemicals 
Doxorubicin was obtained from Roger Bellon laboratories (Neuilly, 
France), [3H]vinblastine and [3H]azidopine were purchased from Amer- 
sham (Buck, UK). RU 486 was a gift from Roussel-Udaf (Romainville, 
France). Verapamil and progesterone w re supplied by Biosedra labo- 
ratories (Levallois-Perret, France) and Sigma Chemicals Co. (St. Louis, 
MO, USA), respectively. 
2.2. Cell culture 
RHC1 rat hepatoma ceils were obtained from a chemically induced 
liver tumor [12] and the normal rat liver epithelial cell SDVI was 
established in our laboratory from the liver of 10-day-old Sprague- 
Dawley rats according to the procedure of Williams et al. [13]. RHC1 
and SDVI cells were grown in Williams' medium supplemented with 
10% fetal calf serum. RHC1 cells displayed a constitutive overexpres- 
sion of functional P-gp [12] while SDVI cells had not detectable P-gp; 
they were used as drug-resistant and drug-sensitive c lls, respectively. 
Multidrug-resistant human leukemia cells K562 R7 (kindly provided 
by Dr J.P. Marie, H6tel Dieu, Paris) were cultured in RPMI medium 
supplemented with 10% fetal calf serum. 
Normal rat hepatocytes were prepared by the two-step collagenase 
perfusion method and then maintained in conventional primary culture 
in a medium containing 75% minimal essential medium and 25% me- 
dium 199 [14]. Hepatocytes were used after two days of culture, at 
which time they displayed high levels of P-gp [15]. 
2.3. Intracellular doxorubicin accumulation 
The intraceilular concentration f doxorubicin was estimated by a 
fluorimetric method as described by Schott et al. [16]. Ceils were ex- 
posed to doxorubicin (10 gg/ml) for 2 h with or without reversing agents 
and then washed three times with ice-cold phosphate buffer saline, 
harvested and ultrasonicated. These steps were performed quickly in 
order to avoid any drug efflux. Cellular proteins were precipitated with 
20% trichloroacetic a id. The acid-soluble fraction was used to evaluate 
the intracellular concentration f doxorubicin by fluodmetry, using 
excitation and emission wavelengths of 485 nm and 590 rim, respec- 
tively. Preliminary studies howed that doxorubicin, verapamil and RU 
486 were not cytotoxic at the concentrations used over the incubation 
period. An aliquot of cell lysate was used in parallel to determine 
cellular protein content by the Bio-Rad protein assay [17]. 
*Corresponding author. Fax: (33) 99 54 01 37. 
Abbreviations." MDR, multidrug resistance; P-gp, P-glycoprotein; 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl t trazolium bromide. 
2.4. Evaluation of doxorubicin efflux 
Cells were incubated with doxorubicin (10 gg/ml) for 2 h, washed 
three times with ice-cold phosphate buffer and reincubated in drug-free 
medium for 30 min or 60 min in the absence or presence of either 
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RU 486 or verapamil (10/aM). The intracellular doxorubicin concen- 
tration was further determined as described above. Intracellular drug 
retention was expressed as a percentage of the initial intracellular drug 
accumulation. 
2.5. Drug-sensitivity assay 
The effect of doxorubicin on cell proliferation was evaluated using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl t trazolium bromide 
(MTT) dye assay [18]. Briefly, RHC1 and SDVI cells were seeded at 
60,000 cells/ml in 96-well microplates and cultured with various concen- 
trations of doxorubicin in the absence or presence of RU 486 or vera- 
pamil (10/aM). After 96 h of incubation, cells were incubated with 
0.05% MTT (Sigma) for 2 h at 37°C and the blue formozan product 
formed was further quantified by its absorbance at 540 nm using a 
Titertek Multiscan MCC/340. Growth inhibition was evaluated as IC50, 
i.e. the drug concentration providing a 50% reduction of cell number 
as compared to controls cultured in parallel without RU 486 or vera- 
pamil. 
2.6. Photoaffinity radiolabeling of P-gp with f H]azidopine 
Photoaffinity labelling of P-gp with [3H]azidopine was performed as 
previously reported [19]. Briefly, P-gp containing membrane fractions 
were prepared from two days cultured rat bepatocytes by differential 
centrifugation asdescribed by Germann et al. [20]. Fifty/ag of mem- 
branes protein per assay were incubated in 40 mM phosphate potas- 
sium buffer, 10/aM CaC12, 4% dimethylsulfoxide with 5/aCi [3H]azidop- 
ine in a final volume of 50/al. The mixture was preincubated 1 hat 25 ° C 
in the dark in the absence or presence of nonradioactive competing 
ligand and then irradiated on ice for 10 min with a UV lamp at 254 nm 
(200,000/aJ/cm 2) at a distance of 10 cm. Membrane proteins were then 
separated by molecular weight following electrophoresis on a SDS- 
polyacrylamide (7%) gel. The get was fixed in 25% ethanol/10% acetic 
acid, treated with the fluorographic reagent Amplify (Amersham) for 
30 min, dried, and then exposed to X-ray film at -80°C. 
For Western blot identification of P-gp, 50/ag crude membrane 
proteins were separated on SDS-polyacrylamide (7%) gel and trans- 
ferred onto a nitrocellulose heet. After incubation with C219 monoclo- 
nal antibody [21] (Centocor Inc. Malvern, PA) and [125I]protein A 
(1/aCi) (Amersham, Buck, UK), the blot was washed, dried and autora- 
diographed at -80 ° C. 
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Fig. 1. Effect of various concentrations of RU 486 on doxorubicin 
accumulation i  RHC1 and SDVI cells. Drug-resistant RHCI cells and 
drug-sensitive SDVI cells were incubated for 2 h with I 0/ag/ml doxoru- 
bicin in the presence of various concentrations of RU 486. The intracel- 
lular doxorubicin concentration was determined using the fluorimetric 
method as described in section 2. The values are the mean + S.D. of 
three independent experiments in triplicate. *P < 0.05. 
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Fig. 2. Effect of RU 486, verapamil and progesterone on doxorubicin 
accumulation i  RHC1 cells. Drug-resistant RHC 1 cells were incubated 
for 2 h with 10/ag/ml doxorubicin either alone (D) or in the presence 
of 10/aM verapamil (D+V), or 10/aM RU 486 (D+RU) or 10/aM 
progesterone (D + P). The intracellular doxorubicin concentration was 
determined using the fluorimetric method as described in section 2. The 
values are the mean + S.D. of three independent experiments in tripli- 
cate. *P < 0.05. 
2. 7. Statistical analysis 
The results of doxorubicin accumulation and efflux studies were 
analyzed by the Student's t-test. The criterion of significance of the 
differences between the means (+ S.D.) was *P < 0.05. 
3. R ~  
In order to determine whether RU 486 was able to affect 
anticancer drug accumulat ion i  cells overexpressing P-gp, in- 
tracellular levels of doxorubicin were estimated in rat drug- 
resistant RHC1 cells in the presence or absence of various 
concentrations of RU 486. Results indicated that the antipro- 
gestatin agent strongly increased cellular doxorubicin reten- 
tion. This effect was dose-dependent and began at 5 gM (Fig. 
1). The concentrat ion of 10 gM,  which allowed to enhance 
cellular doxorubicin accumulat ion by approximately 4-fold, 
was retained in further experiments since it is in the range of 
RU 486 plasma concentrat ions usually observed in humans 
after oral administrat ion of the drug [22]. In contrast o RHC 1 
cells, SDVI drug-sensitive cells did not display any change in 
intracellular doxorubicin levels in the presence of RU 486 what- 
ever the concentrat ion used (Fig. 1). The increase in RHC 1 cell 
doxorubicin accumulat ion obtained with 10 gM RU 486 was 
similar to that observed with 10 gM verapamil (Fig. 2). By 
contrast progesterone used at the same concentrat ion of 10 gM 
had a weaker effect on drug retention (Fig. 2). 
Act ion of RU 486 on doxorubicin export out of RHC1 cells 
was next determined by drug efflux experiments. RU 486 was 
found to strongly inhibit the loss of cellular doxorubicin occur- 
ring during post- incubation i  drug-free medium (Fig. 3). Sim- 
ilar results were observed with verapamil. 
The effect of RU 486 on doxorubicin sensitivity of RHC1 
cells was then monitored using the MTT dye assay. The anti- 
progestatin drug used at a non-toxic concentrat ion of 10 gM 
was thus evidenced to strongly decrease RHC1 cell resistance 
to doxorubicin (Table 1). Indeed, addit ion of RU 486 led to a 
reduction by 59-fold of doxorubicin IC5o values and this chemo- 
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Fig. 3. Effect of RU 486 on doxorubicin efttux from RHC1 cells. 
Drug-resistant RHC1 cells were incubated for 2 h with 10 /ag/ml 
doxorubicin, washed three times with ice-cold phosphate buffer and 
incubated again in drug-free medium for either 30 min or 60 min. These 
studies were performed in the absence of modulator agent ( - - l - - )  or 
in the presence of either verapamil (---O--) or RU 486 (--&--) at 
10/aM. Intracellular doxorubicin concentration was then determined 
using the fluorimetric method as described in section 2. Intracellular 
retained rug values were expressed relative to the initial drug accumu- 
lation values. The values are the mean + S.D. of three independent 
experiments in triplicate. *P < 0.05. 
sensitization was similar to that observed with 10/aM vera- 
pamil. By contrast, RU 486 had no major effect on SDVI cell 
sensitivity to doxorubicin. 
In order to establish whether RU 486 was also active in 
multidrug resistant cells other than RHC1 cells, its effect on 
cellular doxorubicin accumulation was investigated in human 
leukemia K562 R7 cells and in two-day-old primary cultures of 
normal rat hepatocytes, which both markedly overexpressed 
P-gp [12]. Results demonstrated that 10/aM RU 486, like vera- 
pamil, strongly enhanced doxorubicin retention in both leu- 
kemia K562 R7 cells and cultured normal rat hepatocytes 
(Fig. 4). 
The effect of RU 486 on drug-binding to P-gp was further 
analysed with [3H]azidopine. This compound is a photoaffinity 
ligand for P-gp [19] and was found to react with a band at about 
150 kDa in cultured rat hepatocytes which was identified as 
P-gp by Western blot (Fig. 5B). RU 486 was shown to inhibit 
Table 1 
Effects of RU 486 and verapamil on doxorubicin cytotoxicity to RHC 1 
and SDVI cell lines 
Drugs Doxorubicin IC5o (ng/ml) 
RHC1 cells SDVI ceils 
None 1039 + 193 2.50 + 0.40 
RU 486 17.6 + 3.4 (59) 1.38 + 0.33 (1.8) 
Verapamil 19.2 + 2.4 (54) 2.09 + 0.24 (1.2) 
Cells were cultured for 96 h with various concentrations of doxorubicin 
in the presence or absence of RU 486 or verapamil (10/aM). Drug 
effects on cell proliferation were determined using the MTT assay as 
described in section 2. Growth inhibition is expressed as IC5o, i.e. the 
drug concentration providing a 50% reduction of cell numbers as com- 
pared to control cultured in parallel without drugs. Each value repre- 
sents the mean (+ S.D.) of at least two independent experiments in
quadruplicate. Numbers in parentheses indicate the x-fold reversion. 
radiolabelling in a dose-dependent manner (Fig. 5A) indicating 
that the antiprogestatin agent competed with azidopine. 
4. Discussion 
The results reported in the present study strongly evidence 
that RU 486, a compound known for its antiprogestatin prop- 
erties, can also modulate anticancer drug accumulation and 
activity in multidrug resistant cells overexpressing P-gp. In- 
deed, RU 486 enhanced cellular retention and antiproliferative 
effect of doxorubicin in rat RHC1 resistant cells. It also aug- 
mented doxorubicin accumulation in human K562 resistant 
cells, therefore indicating that it is active in both human and 
rodent multidrug resistant cells. Moreover, vinblastine reten- 
tion levels in RHC1 cells were found to be enhanced by 17-fold 
in the presence of RU 486 (data not shown), thus demonstrat- 
ing that the effect of the antiprogestatin drug is not limited to 
doxorubicin. By contrast, RU 486 had no major effect on 
doxorubicin sensitivity and accumulation in drug-sensitive 
SDVI cells. These results therefore indicate that the action of 
RU 486 is restricted to multidrug resistant cells and is thus not 
a general chemosensitization f cells toward anticancer drug 
regardless of their level of resistance. 
The enhancement in doxorubicin retention in RHC1 cells by 
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Fig. 4. Effect of RU 486 and verapamil on doxorubicin accumulation 
in K562 R7 cells and in cultured rat hepatocytes. Human multidrug- 
resistant leukemia K562 R7 cells (A) and two-days cultured rat hepato- 
cytes (B) were incubated with 10/ag/ml doxorubicin for 2 h either alone 
(D) or in the presence of 10/aM verapamil (D + V), or 10/aM RU 486 
(D + RU). The intracellular doxorubicin concentration was then deter- 
mined using the fluorimetric method as described in section 2. The 
values are the mean + S.D. of three independent experiments in tripli- 
cate. *P < 0.05. 
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Fig. 5. Effect of RU 486 on [3H]azidopine labeling of P-glycoprotein 
(P-gp) protein. Crude membrane proteins (50/lg/lane) prepared from 
two-day-old cultured rat hepatocytes were (A) photolabeled with 
[3H]azidopine in the absence (lane 1) or presence ofRU 486 at 10/.lM, 
100 uM or 200 uM (lanes 2, 3 and 4, respectively) and (B) used for P-gp 
detection by Western blot analysis with monoclonal ntibody C219. 
The size of molecular standards (in kDa) is indicated on the left of (A). 
cancer drugs linked, at least partly, to an inhibition of liver and 
kidney P-gp. 
A major obstacle to the clinical use of many chemosensitizer 
agents is linked to the fact that they act at elevated concentra- 
tions which are difficult to obtain in vivo partly owing to ad- 
verse effects. Indeed the use of verapamil at relevant anti-MDR 
concentrations is limited by the appearance of indesirable car- 
diac toxicity [26]. It is noteworthy that RU 486 downmodulated 
drug resistance at a 10/zM concentration which is in the range 
of the plasma concentrations observed in humans after a single 
oral dose [22]. These data suggest that RU 486 could have an 
actual effect in vivo on drug-resistant cells without major toxic- 
ity. This potential clinical relevance of the use of RU 486 as a 
chemosensitizer agent should be determined by further studies. 
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RU 486 was associated with a decrease in doxorubicin export 
out of cells as assessed by drug efflux experiments. These data 
indicate that the antiprogestatin agent seems to act by inhibit- 
ing P-gp-mediated drug transport. This conclusion isalso sup- 
ported by a recent report by Gruol et al. [23] who demonstrated 
that the antiprogestatin agent blocked the efflux of the P-gp 
substrate dye rhodamine 123 in murine resistant cells. Moreo- 
ver, RU 486 was shown to compete with the P-gp photoaffinity 
ligand azidopine, thereby suggesting that inhibitory effect on 
P-gp function is probably related to direct interactions with 
drug binding sites on P-gp. Such a mechanism of action has 
already been reported for many chemosensitizer agents, includ- 
ing verapamil and cyclosporin [4]. 
At 10/zM RU 486 was as effective as verapamil in increasing 
doxorubicin concentration a d activity in RHC1 cells as dem- 
onstrated by drug-sensitivity and -accumulation experiments. 
By contrast, the antiprogestatin agent had a much stronger 
effect on doxorubicin retention than progesterone. This dis- 
crepancy could reflect particular structural features displayed 
by RU 486. Indeed, RU 486 differs from progesterone by a 
1 lfl-(dimethyl amino phenyl) substitution thought o be in- 
volved in its antihormone properties and which constitutes a 
tertiary amine side group [11]. Such a structure has been previ- 
ously demonstrated to be crucial for anti-P-gp activity of many 
chemosensitizers, including phenothiazines and dipyridamole 
analogs [10] and thus could probably account for the potent 
reversing effect of RU 486. 
RU 486 was also found to strongly enhance doxorubicin 
accumulation i  cultured rat hepatocytes, thus suggesting that 
it could inhibit P-gp function in normal cells. Other chemosen- 
sitizer compounds such as verapamil or cyclosporin, have al- 
ready been shown to interact with P-gp in normal tissues [24]. 
Since the physiological substrates for P-gp remain to be deter- 
mined, the exact consequences of this inhibition of P-gp func- 
tion in normal tissues by chemosensitizer agents are difficult o 
predict. However, recent studies have demonstrated that coad- 
ministration of verapamil or cyclosporin with chemotherapeu- 
tic drugs led to pharmacokinetic interactions, particularly a
marked increase in anticancer d ug plasma half-life [25] and this 
situation could reflect a decrease in the clearance of the anti- 
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